# Takeda Pharmaceutical Company

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/takeda-pharmaceutical-company/

## Facts

| Field | Value |
| --- | --- |
| Country | JP |
| Description | Japanese pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320310465 |
| ROR ID | https://ror.org/04hjbmv12 |
| Works | 3,523 |

## Funder papers

- [Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors](https://scholariq.org/papers/genome-wide-profiling-of-non-smoking-related-lung-cancer-cells-reveals-common/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria](https://scholariq.org/papers/hemolysis-induced-by-sars-cov-2-mrna-vaccination-in-patients-with-paroxysmal/)
- [Survival and parenteral nutrition dependence in patients aged 65 y and older with short bowel syndrome: a retrospective observational cohort study](https://scholariq.org/papers/survival-and-parenteral-nutrition-dependence-in-patients-aged-65-y-and-older/)
- [Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance](https://scholariq.org/papers/six-month-safety-and-effectiveness-of-teduglutide-in-patients-with-short-bowel/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.